Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer

Diseases of the Esophagus

Volumn 25, Issue 6, 2012, Pages 545-554

  Semrau, R ^a   Herzog, S L ^a   Vallbohmer D ^a   Kocher, M ^a   Holscher A H ^a   Muller R P ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Esophageal neoplasm; Prognosis; Radiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSESTHESIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS CANDIDIASIS; ESOPHAGUS FISTULA; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART ARREST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; HYPESTHESIA; INOPERABLE CANCER; LEUKOPENIA; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SEPTICEMIA; SKIN TOXICITY; THROMBOCYTOPENIA; TRACHEOESOPHAGEAL FISTULA; TREATMENT PLANNING; TUMOR LOCALIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84865011732     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2011.01286.x     Document Type: Article

References (32)

1. Refaely Y, Krasna M J. Multimodality therapy for esophageal cancer. Surg Clin North Am 2002; 82: 729-46.
2. Thomas C R Jr. Current and ongoing progress in the therapy for resectable esophageal cancer. Dis Esophagus 2005; 18: 211-14.
3. Gebski V, Burmeister B, Smithers B M, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-34.
4. Cooper J S, Guo M D, Herskovic A etal. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-7.
5. Herskovic A, Martz K, Al-Sarraf M etal. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-8.
6. Araujo C M, Souhami L, Gil R A etal. A randomized trial comparing radiation therapy versus concomitant radiation therapy and chemotherapy in carcinoma of the thoracic esophagus. Cancer 1991; 67: 2258-61.
7. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2006; (1): CD002092.
8. Minsky B D, Pajak T F, Ginsberg R J etal. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-74.
9. Ishikawa H, Sakurai H, Yamakawa M etal. Clinical outcomes and prognostic factors for patients with early esophageal squamous cell carcinoma treated with definitive radiation therapy alone. J Clin Gastroenterol 2005; 39: 495-500.
10. Neuhof D, Neumayer F, Einbeck W etal. Retrospective evaluation of combined modality treatment and prognostic factors in patients with esophageal cancer. Acta Oncologica 2005; 44: 168-73.
11. Wolf M, Zehentmayr F, Niyazi M etal. Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. Strahlenther Onkol 2010; 186: 374-81.
12. Schroder W, Bollschweiler E, Kossow C, Holscher A H. Preoperative risk analysis - a reliable predictor of postoperative outcome after transthoracic esophagectomy? Langenbecks Arch Surg 2006; 391: 455-60.
13. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
14. Cox D R, Oakes D. Analysis of Survival Data. London: Chapman Hall, 1984.
15. al-Sarraf M, Martz K, Herskovic A etal. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15: 277-84.
16. Coia L R, Engstrom P F, Paul A R, Stafford P M, Hanks G E. Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. Int J Radiat Oncol Biol Phys 1991; 20: 29-36.
17. Kaneko K, Ito H, Konishi K etal. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer 2003; 88: 18-24.
18. Liu Y P, Ma L, Wang S J etal. Prognostic value of lymph node metastases and lymph node ratio in esophageal squamous cell carcinoma. Eur J Surg Oncol 2010; 36: 155-9.
19. Schmidt S C, Schlechtweg N, Veltzke-Schlieker W etal. [Clinical and pathological prognostic factors for cancers of the esophagogastric junction.] Zentralbl Chir 2009; 134: 455-61.
20. Peyre C G, Hagen J A, DeMeester S R etal. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248: 549-56.
21. Peyre C G, Hagen J A, DeMeester S R etal. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann Surg 2008; 248: 979-85.
22. Schneider P M, Baldus S E, Metzger R etal. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg 2005; 242: 684-92.
23. Coia L R, Minsky B D, Berkey B A etal. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 patterns of care study. J Clin Oncol 2000; 18: 455-62.
24. Warnecke-Eberz U, Vallbohmer D, Alakus H etal. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg 2009; 13: 1411-21.
25. Vallbohmer D, Brabender J, Metzger R, Holscher A H. Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors. J Gastrointest Surg 2010; 14 (Suppl 1): S75-80.
26. Grimminger P, Vallbohmer D, Hoffmann A etal. Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer. J Surg Oncol 2009; 100: 447-51.
27. Ogawa K, Chiba I, Morioka T etal. Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. Anticancer Res 2011; 31: 2351-9.
28. Bollschweiler E, Metzger R, Drebber U etal. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol 2009; 20: 231-8.
29. Bedenne L, Michel P, Bouche O etal. Chemoradiation followed by surgery compared with chemoradiation alone insquamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-8.
30. Stahl M, Stuschke M, Lehmann N etal. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23: 2310-17.
31. RTOG 0436. [Cited 12 Nov 2011.] Available from URL: http://clinicaltrials.gov/ct2/show/NCT00655876?term=rtog+0436&rank=1, Vol. 2010, 2010.
32. Sreedharan A, Harris K, Crellin A, Forman D, Everett S M. Interventions for dysphagia in oesophageal cancer. Cochrane Database Syst Rev 2009; (4): CD005048.